ID   CCC-5
AC   CVCL_LM83
SY   CCC5
DR   cancercelllines; CVCL_LM83
DR   DepMap; ACH-002647
DR   DSMZ; ACC-810
DR   DSMZCellDive; ACC-810
DR   Wikidata; Q54808767
RX   CelloPub=CLPUB00408;
RX   PubMed=35640676;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 60.5 hours (CelloPub=CLPUB00408); 2-3 days (DSMZ=ACC-810).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (DepMap=ACH-002647).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (CelloPub=CLPUB00408).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ=ACC-810
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 15
ST   D19S433: 14
ST   D21S11: 29,31
ST   D2S1338: 20,25
ST   D3S1358: 14,17
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   FGA: 24
ST   Penta D: 9,10
ST   Penta E: 13,14
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 19-12-24; Version: 13
//
RX   CelloPub=CLPUB00408;
RA   Zach S., Grun J., Bauer A.T., Pilarsky C., Grutzmann R., Weng H.-L.,
RA   Dooley S., Wilhelm T.J., Gaiser T., Ruckert F.;
RT   "CCC-5, a new primary cholangiocellular cell line.";
RL   Int. J. Clin. Exp. Pathol. 10:2451-2460(2017).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//